SLDB is trading at $9.27 (+5.40%) as it extends a two-day rally driven by positive clinical data for its experimental Duchenne muscular dystrophy treatment.
- The stock continues to climb following a 10.2% surge on June 23, which was triggered by updates regarding its gene therapy candidate.
- Today's advance appears to be driven by carryover momentum from the recent catalyst, further supported by a firmer broader market.